RDNT

ANALYST NOTE: RDNT (RadNet, Inc.) Date: 2026-06-20 Current Price: $53.74

1. Structural Readiness

State: Forming

• Conservative Entry: — (Awaiting confirmed breakout)
• Aggressive/Pre-Breakout Entry: — (Not actionable on its own; requires confirmation)
• Breakout Level: — (To be defined by the high of the current consolidation range once the breakout fires.)
• Current Price: $53.74
• Extension: — (No extension data provided; price is currently within the consolidation range.)
• ATR Context: Current ATR is 5.3% (High). This indicates elevated volatility, which is consistent with a "Growth Leader" archetype in a forming setup. The ATR-at-breakout is not yet established.

2. Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Diagnostics (Tier Direct, High Confidence) Secondary Exposure: AI-Enabled Healthcare Infrastructure

RadNet operates as a direct beneficiary of the secular shift toward advanced diagnostics, which is a critical enabler for the broader Biotech and GLP-1 ecosystem. As GLP-1 therapies expand patient populations and require rigorous metabolic and oncological monitoring, the demand for high-fidelity imaging (PET/CT, MRI) and AI-driven screening increases.

• Directness: RadNet is a "Tier Direct" member. The company does not merely supply equipment; it operates the infrastructure (435 centers) where these diagnostics occur.
• Thesis Weighting: The company benefits from a dual-engine secular tailwind:
• Volume Growth: Driven by an aging demographic (65+ population growing to 23% by 2054) and the clinical necessity of advanced imaging for chronic disease management.
• Technology Adoption: The integration of AI (via iCAD, See-Mode, CIMAR, Gleamer) creates a "flywheel" effect where software adoption drives hardware utilization and revenue stickiness.

3. Business Analysis

Business Model: RadNet is a national provider of diagnostic imaging services, operating through a hybrid model of directly owned centers and hospital joint ventures. The business generates revenue through procedural fees and leverages a "Digital Health" segment that provides AI-enabled software solutions to third parties and internal centers.

Key Operational Metrics (as of Q1 2026 / March 31, 2026):

• Network Scale: Operated 435 centers across 8 states (AZ, CA, DE, FL, MD, NJ, NY, TX) as of March 31, 2026, up from 418 centers as of December 31, 2025.
• Advanced Imaging Mix: 29.3% of procedural volume was from advanced imaging in Q1 2026, up from 26.9% in Q1 2025 (a 235 basis point increase).
• Segment Growth:
• PET/CT: Increased 35.2% in aggregate and 14.7% on a same-center basis.
• Imaging Centers: Same-center revenue grew 8.9%, driven by higher fees and increased volumes.
• Acquisition Activity:
• Completed two acquisitions in January 2026: *Radiology Regional* (13 centers in SW Florida) and *Northwest Radiology* (6 centers in Indianapolis).
• Announced a new joint venture with Trinity Health's Saint Alphonsus Health System (Boise, ID) yielding ~$30M in annual revenue with 5 centers.
• Digital Health & ARR:
• Annual Recurring Revenue (ARR) reached $97 million in Q1 2026, representing 95% year-over-year growth.
• Management guidance: On plan to reach >$140 million ARR by year-end 2026.
• Pipeline: $7 million in signed ARR secured but not yet reflected in Q1 figures.
• Portfolio: Integrated four AI acquisitions (iCAD, See-Mode, CIMAR UK, Gleamer) with early go-live momentum (e.g., Gleamer X-Ray in California, April 2026).
• Customer Base: 2,890+ customers worldwide; most widely used lung cancer screening solution in the UK.

4. Archetype and Conviction

Archetype: Growth Leader Fit Rationale: RadNet fits the "Growth Leader" archetype due to its double-digit revenue growth, aggressive M&A strategy, and successful integration of high-margin digital health solutions. The company is not a deep value recovery or a cyclical play; it is executing a structural expansion of its service footprint and technology stack.

Conviction Stack:

• Thesis Strength: High. The secular demand for advanced imaging is robust, and RadNet is positioned at the intersection of volume growth (aging population) and margin expansion (AI integration).
• Evidence Quality: Strong. The evidence base (E1–E23) provides granular, point-in-time data on volume mix, same-center growth, and ARR expansion. The consistency between earnings transcripts and SEC filings reinforces the narrative.
• Structural Quality: High. The company has successfully integrated multiple acquisitions (iCAD, etc.) and is expanding its joint venture model, which reduces capital intensity while increasing market reach.
• Rerating Potential: Significant. The transition from a pure imaging services provider to a "Digital Health" platform with $140M+ ARR potential offers a multiple expansion opportunity if the market re-rates the company based on its software recurring revenue.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Confirmation of the >$140M ARR target by year-end 2026.
• Continued expansion of the advanced imaging mix beyond 30%.
• Successful integration of the new joint ventures (Boise, Florida, Indiana) showing immediate EBITDA accretion.

What Would Invalidate the Case:

• Significant slowdown in same-center revenue growth or a decline in advanced imaging volume mix.
• Failure to integrate the recent AI acquisitions, leading to write-downs or margin compression.

Gaps in Evidence Base:

• Breakout Level: The specific price point required to confirm the breakout is not yet defined.
• Margin Details: While EBITDA growth is mentioned ($5M increase), specific margin percentages for the Digital Health segment vs. Imaging Centers are not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key evidence: 95% YoY ARR growth to $97M with a clear path to $140M; 35.2% aggregate growth in PET/CT procedures; successful integration of 4 AI acquisitions expanding the digital health moat. Key risks: Integration complexity of recent M&A; potential regulatory headwinds on AI/ML medical devices; volatility in reimbursement rates. Sizing hint: Position size should reflect the "Forming" setup status; allocate based on the conviction in the thesis while respecting the need for a confirmed breakout. Expected path: Management expects ARR to exceed $140M by year-end 2026; structural implications include a shift in revenue mix toward higher-margin digital solutions and continued geographic expansion via joint ventures. Expected horizon: 6 to 12 months for the thesis to fully play out as ARR targets are met and integration synergies are realized.